Rip Ballou, ADVANCE Program Lead and Principal Investigator at IAVI

ADVANCE Senior Scientific Advisor and Project Lead, HIV bnAbs

W. Ripley (“Rip”) Ballou, M.D., is senior scientific advisor to ADVANCE and also leads IAVI's work on developing broadly neutralizing antibodies for HIV prevention.

Ballou previously was Vice President and Head at GSK Global Vaccines U.S. R&D Center in Rockville, Maryland. Prior to that, he was Vice President and Head, Clinical Research and Translational Science, Vaccine Discovery and Development at GSK Vaccines. He also served as Deputy Director for Vaccines, Infectious Diseases Development, Global Health, at the Bill & Melinda Gates Foundation. Trained in internal Medicine and infectious diseases, he began his work on vaccines at the Walter Reed Army Institute of Research where he led the team that with GSK co-developed RTS,S, the world’s most advanced malaria vaccine.

Ballou received his M.D. from Emory University School of Medicine and completed his residency and fellowship in infectious diseases at Walter Reed Army Medical Center.